236
Views
43
CrossRef citations to date
0
Altmetric
Original Research

New inhalation-optimized itraconazole nanoparticle-based dry powders for the treatment of invasive pulmonary aspergillosis

, , , &
Pages 5475-5489 | Published online: 18 Oct 2012

References

  • HopeWWInvasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosisMed Mycol200947Suppl 1S291S29819306226
  • PfallerMADiekemaDJEpidemiology of invasive mycoses in North AmericaCrit Rev Microbiol20103615320088682
  • LeJSchillerDSAerosolized delivery of antifungal agentsCurr Fungal Infect Rep201049610220502511
  • LabirisNRDolovichMBPulmonary drug delivery. Part II: the role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medicationsBr J Clin Pharmacol20035660061214616419
  • DuretCWauthozNSebtiTVanderbistFAmighiKSolid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion propertiesInt J Pharm201242810311322414388
  • MobleyCHochhausGMethods used to assess pulmonary deposition and absorption of drugsDrug Discov Today2001636737511267923
  • MüllerRHJacobsCKayserONanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the futureAdv Drug Deliv Rev20014731911251242
  • RabinowBENanosuspensions in drug deliveryNat Rev Drug Discov2004378579615340388
  • SungJCPulliamBLEdwardsDANanoparticles for drug delivery to the lungsTrends Biotechnol20072556357017997181
  • ShamJOZhangYFinlayWHRoaWHLobenbergRFormulation and characterization of spray-dried powders containing nanoparticles for aerosol delivery to the lungInt J Pharm200426945746714706257
  • YangWPetersJIWilliamsRO3rdInhaled nanoparticles – a current reviewInt J Pharm200835623924718358652
  • WeersJGDispersible powders for inhalation applicationsInnov Pharm Technol20001111116
  • El GendyNBerklandCCombination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomerationPharm Res2009261752176319415471
  • El GendyNGormanEMMunsonEJBerklandCBudesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolutionJ Pharm Sci2009982731274619130469
  • PilcerGVanderbistFAmighiKPreparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary deliveryInt J Pharm200936516216918782609
  • SalemHAbdelrahimMEidKASharafMNanosized rods agglomerates as a new approach for formulation of a dry powder inhalerInt J Nanomedicine2011631132021383856
  • DaviskasEAndersonSDJaquesACharltonBInhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosisChest201013786186819880909
  • HindsWCAerosol Technology: Properties, Behavior, and Measurement of Airborne Particles2nd edNew YorkWiley19994247
  • SonYJMcConvilleJTDevelopment of a standardized dissolution test method for inhaled pharmaceutical formulationsInt J Pharm2009382152219665533
  • PhamSWiedmannTSNote: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactantJ Pharm Sci2001909810411064383
  • Van EerdenbrughBVan denMGAugustijnsPTop-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid productsInt J Pharm2008364647518721869
  • HecqJDeleersMFanaraDVranckxHAmighiKPreparation and characterization of nanocrystals for solubility and dissolution rate enhancement of nifedipineInt J Pharm200529916717715996838
  • KeckCMMullerRHDrug nanocrystals of poorly soluble drugs produced by high pressure homogenisationEur J Pharm Biopharm20066231616129588
  • Van EerdenbrughBVan den MooterGAugustijnsPTop-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid productsInt J Pharm2008364647518721869
  • PilcerGAmighiKFormulation strategy and use of excipients in pulmonary drug deliveryInt J Pharm201039211920223286
  • WangBZhangWZhengWMujumdarASHuangLProgress in drying technology for nanomaterialsDrying Technol200423118
  • Van EerdenbrughBFroyenLVan HumbeeckJMartensJAAugustijnsPVan den MooterGDrying of crystalline drug nanosuspensions – the importance of surface hydrophobicity on dissolution behavior upon redispersionEur J Pharm Sci20083512713518644441
  • ChaubalMVPopescuCConversion of nanosuspensions into dry powders by spray drying: a case studyPharm Res2008252302230818509597
  • ChanHKGondaIDevelopment of a systematic theory of suspension inhalation aerosols. 2. Aggregates of monodisperse particles nebulized in polydisperse dropletsInt J Pharm198841147157
  • BinksBPParticles as surfactant – similarities and differencesCurr Opin Colloid Interface Sci200272141
  • MajumderMRendallCEukelAWangJNatnaelBehabtuPintCLiuTOrbaekAMirriFNamJ,BarronAHaugeRSchmidtHPasqualiMOvercoming the “Coffee-Stain” Effect by Compositional Marangoni-Flow- Assisted Drop-DryingJ Phys chem201211665366542
  • TsapisNBennettDJacksonBWeitzDEdwardsDATrojan particles: large porous carriers of nanoparticles for drug deliveryProc Natl Acad Sci U S A200299120011200512200546
  • StroockADDertingerSKAjdariAMezicIStoneHAWhitesidesGMChaotic mixer for microchannelsScience200229564765111809963
  • HaoJLiSKMechanistic study of electroosmotic transport across hydrated nail plates: effects of pH and ionic strengthJ Pharm Sci2008975186519718386836
  • DuretCWauthozNSebtiTVanderbistFAmighiKNew respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosisPharm Res2012291028455922644590
  • MorrisGKokkiMHAndersonKRichardsonMDSampling of Aspergillus spores in airJ Hosp Infect200044819210662557
  • EduardWFungal spores: a critical review of the toxicological and epidemiological evidence as a basis for occupational exposure limit settingCrit Rev Toxicol20093979986419863384
  • PasqualottoACDifferences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavusMed Mycol200947Suppl 1S261S27018654921
  • WeilerCEgenMTrunkMLangguthPForce control and powder dispersibility of spray dried particles for inhalationJ Pharm Sci20109930331619533606
  • SoubaniAOChandrasekarPHThe clinical spectrum of pulmonary aspergillosisChest20021211988199912065367
  • ChewNYTangPChanHKRaperJAHow much particle surface corrugation is sufficient to improve aerosol performance of powders?Pharm Res20052214815215771241
  • ByronPRPeartJStaniforthJNAerosol electrostatics. I: Properties of fine powders before and after aerosolization by dry powder inhalersPharm Res1997146987059210184
  • YangWJohnstonKPWilliamsRO3rdComparison of bioavailability of amorphous versus crystalline itraconazole nanoparticles via pulmonary administration in ratsEur J Pharm Biopharm201075334120102737
  • DenningDWHopeWWTherapy for fungal diseases: opportunities and prioritiesTrends Microbiol20101819520420207544
  • ZhangJWuLChanHKWatanabeWFormation, characterization, and fate of inhaled drug nanoparticlesAdv Drug Deliv Rev20116344145521118707
  • PetersKKrussBBeckerRMüllerRHPharmaceutical nanosuspensions for medicament administration as systems with increased saturation solubility and rate of solution United States patent US005858410A1121999
  • MüllerRHPetersKNanosuspensions for the formulation of poorly water soluble drugs. I. Preparation by a size reduction techniqueInt J Pharm1998160229237
  • LeeRWShawJMMcShaneJWoodRWParticle size reductionLiuRWater-Insoluble Drug FormulationDenverInterpharm Press2000455492
  • KayaertPAnneMVan denMGBead layering as a process to stabilize nanosuspensions: influence of drug hydrophobicity on nanocrystal reagglomeration following in-vitro release from sugar beadsJ Pharm Pharmacol2011631446145321988425